Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.

Participants needed: 474
Trial details
Phase: Phase 3Age: 12-12Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Apr 17, 2026Locations: 1
Eligibility criteria

Participant must be 12 months to 12 years of age, inclusive, at the time of sign... [+1]

Participants with a history of exposure to varicella through contact with a vari... [+3]

Read more
Status: Recruiting

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

Participants needed: 18
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Nov 4, 2025Locations: 10
Eligibility criteria

Participants must be ≥ 18 years of age or age considered as adult in the respect... [+16]

Women who are pregnant, planning to become pregnant during the study, or are bre... [+16]

Read more
Status: Recruiting

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).

Participants needed: 9
Trial details
Phase: Phase 1Age: 12-18Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Aug 28, 2025Locations: 5
Eligibility criteria

Participants with documented MPS IIIA diagnosis [+1]

Participants with significant non-MPS IIIA related central nervous system impair... [+4]

Read more
Status: Recruiting

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.

Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 19-64Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Jul 10, 2025Locations: 1
Eligibility criteria

Healthy adults aged 19 to 64 years old as of the date of written consent. [+1]

Individuals who have received a vaccine within 4 weeks prior to administration o... [+3]

Read more
Status: Recruiting

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients

Participants needed: 105
Trial details
Phase: Phase 3Age: 18-64Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Jun 25, 2025Locations: 8
Eligibility criteria

Aged ≥18 and <65 years at the time of signing the consent form [+3]

Subject with history of anaphylaxis to any component of the investigational prod... [+12]

Read more